Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

Home

/

TLSI

T

TriSalus Life Sciences, Inc. (TLSI)

NGM – Real vaqt narxi. Valyuta: USD

5.71

-0.03 (-0.52%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

5.71

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences Q2 Earnings Call Highlights

TriSalus Life Sciences NASDAQ: TLSI reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, as demand for its TriNav pressure-enabled drug delivery system increased. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

TriSalus Life Sciences Reports Second Quarter 2026 Results

TriSalus Life Sciences Reports Second Quarter 2026 Results

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f.

Videolar

No Data

There is no data to display

Press-relizlar

TriSalus Life Sciences Reports Second Quarter 2026 Results

TriSalus Life Sciences Reports Second Quarter 2026 Results

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our f.